Frontlight ResearchEarly access
CompletedNo phase
The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET
Key facts
- Who runs it
- Shandong University of Traditional Chinese Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 480 people enrolled
- Started
- 15 Sept 2023
- Ended
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Erzhi Tiangui Granule
- Erzhi Tiangui Placebo
- Record updated
- 13 April 2026
Who can take part
- Age
- 35 years to 43 years
- Sex
- Women only
- Healthy volunteers
- Can take part
Show the full registry criteria (2)Hide the full registry criteria
Other criteria
- Women aged 35 to 43 years with POR who were scheduled for IVF or intracytoplasmic sperm injection (ICSI) treatment were eligible for enrollment. The diagnosis of POR was based on the Bologna criteria
- Women were excluded if they: (i) had a body mass index (BMI) ≥ 35 kg/m2; (ii) failed to obtain clinical pregnancy after three or more IVF/ICSI cycles; (iii) had a history of two or more recurrent pregnancy losses; (iv) were diagnosed with uterine abnormalities using hysteroscopy or diagnosed with hydrosalpinx using hysterosalpingography; (v) had a history of chemotherapy with cytotoxic agents, pelvic radiotherapy, or severe systemic diseases; (vi) had taken Chinese herbal medicines or other therapies affecting ovarian function within three months before study enrollment; or (vii) were allergic to the ingredients of EZTG granules or placebo
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized controlled trial aims to determine whether Erzhi Tiangui Formula can optimize the reproductive outcomes of elderly patients with expected poor ovarian response, and to provide a new approach to traditional Chinese medicine assisted in vitro fertilization and embryo transfer (IVF-ET).
The 2 groups in the trial
- EZTG groupTreatment being tested
Treatment: Erzhi Tiangui Granule
- Control groupPlacebo, for comparison
Treatment: Erzhi Tiangui Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Erzhi Tiangui Granules on Live Birth Rate in Advanced-age Women With Poor Ovarian Response Undergoing in Vitro Fertilization: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
- Record updated
- 13 April 2026